Risk factors and predictors of adverse outcomes of in paediatric febrile neutropenia

SA Journal of Oncology

Field Value
Title Risk factors and predictors of adverse outcomes of in paediatric febrile neutropenia
Creator Adekunle, Motunrayo O. Davidson, Alan Hendricks, Marc
Subject Paediatric Oncology febrile neutropenia; cancer; chemotherapy; children; risk factors; adverse outcomes
Description Background: Febrile neutropenia (FN) is the commonest acute complication of cancer treatment in children. The identification of patients at risk for FN as well as adverse outcomes has been described.Aim: To evaluate the prevalence and potential risk factors for FN and describe adverse outcomes in a cohort of children treated for cancer.Setting: The study was carried out in a paediatric oncology unit in a children’s hospital, Cape Town, South Africa.Methods: A retrospective study from 01 January 2017 to 31 December 2019 on children with cancer at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa.Results: Two hundred and sixty-seven episodes of FN occurred in 179 patients. Independent predictors of FN were acute myeloid leukaemia (AML) (p = 0.039), acute lymphocytic leukaemia (ALL) (p = 0.020) and intensive chemotherapy (p ≤ 0.001). Mucositis (p = 0.001), central venous access device (CVAD) placement (p = 0.004), haematologic malignancies (p = 0.040), blood transfusion during FN episode (p  0.001) and severe neutropenia (white cell counts 0.3 × 109 cells/L) (p ≤ 0.001) were risk factors for adverse outcomes. The mortality rate from FN was 3.57%. Independent predictors of adverse outcomes in those with FN were AML (p = 0.001), CVAD placement (p = 0.019) and severe neutropenia (p = 0.005).Conclusion: Treatment related adverse outcomes following chemotherapy-induced FN are likely in children with AML, severe neutropenia and with CVAD placement.Contribution: Adverse outcomes from paediatric febrile neutropenia is high. There is need for clinical decision making aimed at prevention and early identification of individuals at risk. 
Publisher AOSIS
Contributor Michelle Karnemeyer
Date 2023-03-14
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Retrospective
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajo.v7i0.232
Source South African Journal of Oncology; Vol 7 (2023); 8 pages 2523-0646 2518-8704
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajo.org.za/index.php/sajo/article/view/232/731 https://sajo.org.za/index.php/sajo/article/view/232/732 https://sajo.org.za/index.php/sajo/article/view/232/733 https://sajo.org.za/index.php/sajo/article/view/232/734
Coverage Cape Town, South Africa 2017-2019 Patients with febrile neutropenia, age less than 16 years
Rights Copyright (c) 2023 Motunrayo O. Adekunle, Alan Davidson, Marc Hendricks https://creativecommons.org/licenses/by/4.0